



CHARITY WATCHLIST

Breakthrough T1D



EMBRYONIC STEM CELLS

- Within its [Scientific Guidelines](#), which was last updated in 2012, Juvenile Diabetes Research Foundation (JDRF) shows that it funds human embryonic stem cell research:

“JDRF funds research for the derivation of hES from excess embryos created by in vitro fertilization (IVF) for reproductive purposes. This includes stored embryos that are no longer needed for reproductive purposes and embryos determined to be clinically unsuitable for uterine implantation” (p.9).

It also admits using fetal tissue from aborted babies:

“Informed consent for the use of fetal tissue for research should include the following: a) A statement that fetal tissue obtained from an elective termination of pregnancy may be used for research” (p.11).

- In [a blog post from 2010](#) (archived), the JDRF announced its support for an appeals court’s decision to overturn a block on federal funding for human embryonic stem cells:

“Today, we’re pleased to share that an appeals court has lifted that injunction and National Institutes of Health can fund embryonic stem cell research while the legal proceedings continue.”

- JDRF [expresses support](#) for human embryonic stem cell research:

“Harvard stem cell researchers announced that they have made a giant leap forward in the quest to find a truly effective treatment for type 1 diabetes. With human embryonic stem cells as a starting point, the scientists are for the first time able to produce, in the kind of massive quantities needed for cell transplantation and pharmaceutical purposes, human insulin-producing beta cells equivalent in most every way to normally functioning beta cells.

- The Archdiocese of Baltimore [condemns support to JDRF](#) because of its funding and support of research for diabetes using human embryonic stem cells and fetal tissue from aborted babies.

“The Archdiocese of Baltimore does not encourage support, financial or otherwise, for Juvenile Diabetes Research Foundation (JDRF) due to its policies regarding medical research that engages in or endorses practices that violate the dignity of human life, including Human Embryonic Stem Cell Research and the use of fetal tissue derived from abortions.”

- JDRF posted a [timeline](#) in 2022 about its involvement with stem cell therapies, including using and advocating for the use of human embryonic stem cells which it began advocating for in 1999.

Breakthrough T1D (formerly JDRF)
breakthrought1d.org

Tax ID: 23-1907729

200 Vesey Street, 28th Floor
New York, NY
10281

phone: 800.533.2873

Mission

Improve lives by accelerating life-changing breakthroughs to cure, prevent and treat T1D and its complications.

Focus

type 1 diabetes, emergency medical services, philanthropy